Trusted Resources: Education
Scientific literature and patient education texts
Immunomodulatory Drugs in AL Amyloidosis
source: Critical Reviews in Oncology/Hematology
year: 2016
authors: Jelinek T, Kufova Z, Hajek R
summary/abstract:Immunoglobulin light chain amyloidosis (AL amyloidosis) is indeed a rare plasma cell disorder, yet the most common of the systemic amyloidoses. The choice of adequate treatment modality is complicated and depends dominantly on the risk stratification of these fragile patients. Immunomodulatory drugs (IMiDs) are currently used in newly diagnosed patients as well as in salvage therapy in relapsed/refractory patients.
IMiDs have a pleiotropic effect on malignant cells and the exact mechanism of their action has been described recently. Thalidomide is the most ancient representative, effective but toxic. Lenalidomide seems to be more effective, nevertheless the toxicity remains high, especially in patients with renal insufficiency. Pomalidomide is the newest IMiD used in this indication with a good balance between efficacy and tolerable toxicity and represents the most promising compound. This review is focused on the evaluation of all three representatives of IMiDs and their roles in the treatment of this malignant disorder.
organization: University Hospital Ostrava, Czech Republic; University of Ostrava, Czech RepublicDOI: 10.1016/j.critrevonc.2016.01.004
read more
Related Content
-
Nutritional Counseling Improves Quality Of Life and Preserves Body Weight in Systemic Immunoglobulin Light-Chain (AL...Objective: Malnutrition is associated w...
-
Webinar Presentation by Morie Gertz on AL Amyloidosis Overviewhttps://www.youtube.com/watch?v=qscVgShp...
-
Treatment Considerations for Patients Exceeding 10% Plasma Cells – ASG Webinar 11/13https://www.youtube.com/watch?v=4gUXPbOk...
-
Novel Agents for the Treatment of AL Amyloidosis: Dr. Tibor Kovacsovics – ASG Webinar 3/13https://www.youtube.com/watch?v=NrEjyVeJ...
-
FDA Approves Subcutaneous Daratumumab Plus VCd for Newly Diagnosed Light-Chain AmyloidosisThe FDA has approved daratumumab and h...
-
AL Amyloidosis: Hot Topics From ISA 2020https://www.youtube.com/watch?v=n-41ooYJ...
-
Clarification on Prothena AFFIRM and CAEL-101 Global Trials: Muriel Finkel – ASG Webinar 11/13https://www.youtube.com/watch?v=NrEjyVeJ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.